THE CURE
A universal cure-all doesn't exist yet. But a cure for every disease will — through AI-driven drug discovery, CRISPR gene editing, and network medicine. We're compressing the timeline from decades to months.
Where we are on every disease
A living scoreboard of the cure pipeline. 2 diseases already have approved cures for major forms; 5 more are being cured in human trials right now. This is not science fiction — it's the clinic, today.
Bleeding Factor Disorders
Hematology
Hemgenix + Roctavian approved — hemophilia A & B functionally cured today
Blindness & Vision Loss
Ophthalmology
Luxturna approved for inherited blindness; optogenetics restoring light sensitivity
Obesity & Metabolic Disorders
Endocrinology / Bariatric Medicine
GLP-1s delivering 15–25% weight loss; oral versions 1–2 years out
Type 1 Diabetes
Endocrinology / Diabetology
Stem-cell islet transplants (VX-880) producing insulin in trial patients
Cancer
Oncology
Personalized mRNA cancer vaccines in Phase III; CAR-T hitting complete remissions
Heart Disease
Cardiology
One-shot gene editing for cholesterol (PCSK9) in human trials
Lung Disease
Pulmonology
Trikafta transforming cystic fibrosis; CRISPR CFTR correction in development
STATUS REFLECTS APPROVED THERAPIES & ACTIVE TRIALS · NOT MEDICAL ADVICE · TALK TO YOUR DOCTOR
FROM YEARS TO MONTHS: THE AI PIPELINE
Traditional drug discovery takes 10–22 years and costs $2.6 billion per drug. AI, CRISPR, and gene editing don't just speed it up — they fundamentally restructure the process. Every stage compresses. Every bottleneck breaks. One disease at a time, then all of them.
“Think big, start small. Understand the entire process, then automate each stage — from discovery to cure, one individual at a time.”
The Math of Compression
A disease that would have taken 15 years and $2.6B to cure in 2020 can be cracked in under 12 months at a fraction of the cost. The pipeline doesn't just get faster — it gets fundamentally different. AI reads every paper. CRISPR edits the target. Gene therapy delivers the fix. One patient at a time, then all of humanity.
Acceleration Vectors
The medically important directions that could realistically accelerate cures or functional cures — organized from shared cross-cutting priorities to disease-specific strategies.
EACH VECTOR REPRESENTS A CONVERGENCE OF AI, BIOLOGY, AND CLINICAL INFRASTRUCTURE — COMPRESSING WHAT TOOK DECADES INTO YEARS.
The Washout Problem
Clinical trials need clean baselines. But for people who depend on medication to survive, “stop taking everything for six months” isn't science — it's a sentence. Here's what's being done about it.
“Honestly, my body couldn't handle going a full year without any medication.”
— Potential VIVID-6 participant, on the 24-week observational period + 49-week treatment design
The tools to eliminate washout periods exist — organ-on-chip, digital twins, AI-modeled baselines. They're not fully validated for rare bleeding disorders yet, but the regulatory pathways are open and the technology is advancing. The era of asking patients to prove they're sick by stopping their medication is ending. The question is whether it ends fast enough for the people who need VGA039 now.
How a Drug Reaches You
If VGA039 succeeds in Phase 3, here's exactly what happens between “the trial worked” and “the medication is in your hands.” For an orphan biologic with Fast Track designation, the pipeline is well-defined.
Estimated timeline assumes VIVID-6 completes on schedule (Oct 2028), a Priority Review BLA, and no Complete Response Letter. Actual timelines may vary.
The Cure May Have Been Found.
What Do I Do Now?
You can't participate in a late-stage trial. But VGA039 looks genuinely promising — 73–100% bleed reduction, once-monthly, self-injected, works across all VWD types. The goal now isn't to wait. The goal is to become the cleanest, most well-documented, easiest-to-approve patient when this or a similar therapy becomes available.
You want your hematology file to already prove five things:
You truly have VWD or a related bleeding disorder.
Your subtype is correctly classified.
Your bleeding burden is objectively documented.
Current therapies are burdensome, incomplete, unsafe, impractical, or financially difficult.
You are medically safe enough to receive a pro-hemostatic biologic that targets Protein S.
That means the work now is not “wait for approval.” The work now is build the evidence packet.
Don't try to prove need by going untreated. Prove need by building a clean medical record: confirmed VWD subtype, repeated baseline labs, bleeding score, real bleed diary, treatment burden, and safety profile.
“This patient has confirmed clinically significant VWD, has recurrent bleeding and treatment burden despite current options, has documented baseline labs and subtype, and is an appropriate candidate for long-acting prophylaxis when available.”
This is educational information, not medical advice. VGA039 is investigational and not yet approved. All medical decisions should be made with your hematologist or qualified healthcare provider. Lab testing and clinical assessments described here should be ordered and interpreted by your doctor.
Could You Be a Candidate?
This is not medical advice. This is a structured way for you to think through whether a clinical trial conversation with your specialist is worth having — and to walk in prepared, not passive.
The Obligatory (But Genuine) Disclaimer
Talk to your doctor. Seriously. Yes, you probably know more about your specific condition than your GP does — you live in this body 24/7 and they see you for 15 minutes twice a year. But they went to medical school, they understand drug interactions, and they\'re the ones who can actually refer you to trials. This screener generates talking points, not prescriptions. Think of it as arming yourself for a productive conversation with the appropriate human in the loop.
10 questions · ~2 minutes
No data stored. No tracking. Just you and some clarity.
SEARCH ANY DISEASE. GET THE STATUS.
Enter any disease or condition. Our AI generates a real-time status report: current research, AI/CRISPR approaches, key organizations, estimated timeline to breakthrough, and related research from our feed.
THE QUEST TO CURE ALL HUMAN DISEASE
Intelligence wants to solve problems. The hardest, most consequential problem is human suffering. The coagulation cascade — the system that stops bleeding — is one of biology's most intricate networks. Cracking it with AI doesn't just cure blood disorders. It unlocks the pattern for curing everything.
“The phase transition isn't just economic. When intelligence inverts, medicine inverts too. Disease becomes an engineering problem. Suffering becomes optional.”
THE COAGULATION CASCADE
— How bleeding stops, and where it breaksTissue damage exposes Tissue Factor (TF). TF–VIIa activates Factor X and IX, producing a small amount of thrombin — the spark that starts the cascade.
AI can model TF expression patterns to predict bleeding risk before symptoms appear.
Break any link in this chain → bleeding disorder. Overactivate any step → thrombosis. The balance is everything.
BLOOD FACTOR DISORDERS
— The first targetsTHE CASCADE EFFECT
Curing blood factor disorders isn't the destination — it's the first domino. The coagulation cascade touches nearly every system in the body. Master it, and the pattern propagates.
Heart attacks and strokes are clotting events. Mastering the cascade rewrites cardiac medicine.
Tumors hijack coagulation to spread. Anti-clotting AI could starve metastasis.
Antiphospholipid syndrome attacks clotting factors. Understanding the cascade maps the immune terrain.
Every operation is a bleeding risk. AI-guided hemostasis makes the impossible operable.
Pre-eclampsia, miscarriage, HELLP — all coagulation disorders. Fixing the cascade saves two lives.
Cerebral hemorrhage and ischemic stroke. The brain is the most vulnerable organ to clotting failure.
The old world treats symptoms. The new world engineers cures. AI doesn't just read the coagulation cascade — it rewrites it.
Hemostasis is balance: enough clotting to stop bleeding, but enough regulation to avoid thrombosis.
THE ACCELERATION IS VISIBLE
Every node is a research breakthrough. Watch the nodes cluster more tightly in recent months — the compression is accelerating. Filter by domain to see the wave build.